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Abstract To quantify peroxynitrite production during shock, we 
measured oxidation of dihydrorhodamine 123 in rats. In en- 
dotoxic and hemorrhagic shock and splanchic ischemia-reperfu- 
sion, dihydrorhodamine oxidation rapidly increased, which was 
prevented by inhibition of endothelial nitric oxide (*NO) synthase 
(eeNOS). Thus, peroxynitrite is already formed at early stages 
of shock from ecNOS-derived *NO. Overproduction of *NO by 
the inducible NOS at late shock was not associated with addi- 
tional increases in dihydrorhodamine oxidation, ecNOS inhibi- 
tion enhanced ihydrorhodamine oxidation in control rats. These 
latter findings may be explained by *NO-mediated inhibition of 
peroxynitrite-induced ihydrorhodamine oxidation, a phenome- 
non also observed in vitro. 
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1. Introduction 
Peroxynitrite, a potent, reactive oxidant, is formed by the 
reaction of nitric oxide (*NO) with superoxide anion (O;) [1,2]. 
The production of peroxynitrite has been demonstrated or pro- 
posed in a variety of pathophysiological conditions, including 
septic shock [3,4], arthritis [5], acute respiratory distress syn- 
drome [6,7], atherosclerosis [8] ischemia-reperfusion [9,10], in- 
flammatory bowel disease [9,11] and MTPT-mediated neuro- 
toxicity [12]. 
There are limited possibilities for the measurement of per- 
oxynitrite in vivo. Most investigators use semi-quantitative irn- 
munohistochemical methods, based on the measurement of ni- 
trotyrosine immunoreactivity, which is based on the specific 
reaction of peroxynitrite with tyrosine residues of proteins 
[1,2,6,7,13]. The oxidation of dihydrorhodamine 123 to 
rhodamine has been used in in vitro experiments o measure the 
production of peroxynitrite [14]. In the present study, we have 
made an attempt o utilize the oxidation of dihydrorhodamine 
123 to rhodamine to estimate the formation of biologically 
active peroxynitrite in vivo. This method, coupled with the use 
of pharmacological inhibitors o f*NO synthase (NOS), allowed 
us to investigate the time course of peroxynitrite formation in 
rat models of endotoxic and hemorrhagic shock and splanchnic 
ischemia-reperfusion injury. Our data demonstrate that the 
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formation of peroxynitrite already occurs at early stages of 
endotoxic and hemorrhagic shock and reperfusion after splan- 
chnic ischemia. 
2. Materials and methods 
2.1. Materials 
Bacterial lipopolysaccharide (E. coli, serotype No. 0127 :B8), diethyl- 
amine and AN-nitro-e-arginine methyl ester (L-NAME) were obtained 
from Sigma (St. Louis, MO). S-Methyl-isothiourea sulfate (SMT) was 
obtained from Aldrich (St. Louis, MO). Diethylamine:NO was ob- 
tained from RBI (Natick, MA). Dihydrorhodamine 123 (DHR 123) 
and rhodamine were obtained from Molecular Probes (Eugene, OR). 
2.2. Animals and experimental protocols 
Male Wistar rats (Charles River Laboratories, Wilmington, MA) 
were anesthetized with sodium thiopentol (120 mg/kg, i.p.) and instru- 
mented as described [15]. The trachea was cannulated to facilitate 
respiration and rectal temperature was maintained at 37°C using a 
homeothermic blanket. The right carotid artery was cannulated and 
connected to a pressure transducer for the measurement of phasic and 
mean arterial blood pressure (MAP) and heart rate which were digital- 
ized using a Maclab A/D converter (AD Instruments, Milford, MA) 
and stored and displayed on a Macintosh personal computer. The left 
femoral vein was cannulated for the administration of drugs. Upon 
completion of the surgical procedure, cardiovascular parameters were 
allowed to stabilize for 10 min. 
To induce endotoxin shock, separate groups of animals were injected 
with E. coli endotoxin (15 mg/kg i.v.) for 1, 2 or 3 h. At these time 
points, separate groups of rats received an i.v. bolus injection of dihy- 
drorhodamine 123 (DHR 123; 2/zmol/kg in 0.3 ml saline). At 20 rain 
after the injection of DHR, animals were sacrificed, blood was collected 
into heparinized tubes and rhodamine fluorescence was measured as 
described below. To inhibit ecNOS, the NOS isoform present at the 
early phase of shock (at 1 h after endotoxin) [15], separate groups of 
animals were treated with L-NAME (20 mg/kg i.v.) 10 min prior to the 
injection of DHR 123. At 2 h and 3 h after endotoxin, to inhibit both 
ecNOS and iNOS, animals received a high dose (10 mg/kg i.v.) of 
S-methyl-isothiourea sulfate (SMT), a potent inhibitor of NOS [16] 10 
min prior to the injection of DHR 123. In each group, animals were 
sacrificed 20 min after the injection of DHR 123. 
To induce hemorrhagic shock, blood was withdrawn to reduce MAP 
to 50 mmHg [17]. MAP was maintained at this level by further with- 
drawal or re-injection of blood. DHR 123 was injected, in separate 
groups of rats, at 1 h and at 3 h after the initiation of shock and animals 
were sacrificed after an additional 20 rain. To inhibit ecNOS, the NOS 
isoform present at 1 h of hemorrhagic shock [17] a separate group of 
rats were treated with L-NAME (20 mg/kg i.v.), 5 min prior to the 
injection of D HR 123. At 3 h of hemorrhagic shock, in a separate group 
of rats, a high dose of SMT (10 mg/kg) was used to inhibit both ecNOS 
and iNOS. In each group, animals were sacrificed 20 rain after the 
injection of DHR 123. 
To induce splanchnic ischemia nd reperfusion, the mesenteric artery 
was clamped for 45 min, followed by release of the clamp (reperfusion) 
[18]. In this model, DHR 123 was injected at 25 rain after the occlusion 
or at 25 rain after the release of the clamp. In separate groups of rats, 
ecNOS was inhibited with L-NAME (20 mg/kg i.v. as above) 10 rain 
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prior to the injection of DHR 123. Animals were sacrificed 20 min after 
the injection of DHR 123. 
In separate groups of control rats (without shock), DHR 123 was 
injected as described and samples were taken 20 min thereafter. This 
procedure was repeated in control rats pretreated with L-NAME (20 
mg/kg i.v.) for 10 min. 
In all groups of rats, animals received only one injection of DHR 123 
and all animals were sacrificed at 20 rain after its injection; n = 4-6 rats 
were used in all groups. 
2.3. Measurement of plasma rhodamine levels 
After obtaining plasma samples from the various groups of rats, 
fluorescence of rhodamine (an oxidation product of DHR 123 and a 
marker of exposure of DHR 123 to peroxynitrite) was measured in a 
Perkin-Elmer fluorimeter (excitation 500 nm, emission 526 nm, slit 
widths 2.5 and 3.0 nm, respectively) [14]. In subgroups of the plasma 
samples (in samples obtained from control rats and in rats after 3 h of 
endotoxin shock), plasma was exposed to various concentrations of 
peroxynitrite in vitro to determine maximal fluorescence. We have 
found that in vitro exposure to peroxynitrite (100/aM, 30 min) was still 
able to markedly increase fluorescence (to approx. 100 fluorescence 
units from approx. 4-10 units, n = 3), indicating that under the condi- 
tions used, the oxidation of DHR 123 was submaximal in vivo. In a 
separate set of experiments, we have used hydrogen peroxide and per- 
oxynitrite to completely oxidize DHR 123 to rhodamine in vitro in 
order to determine plasma levels of DHR 123 at 20 rain after its 
injection. Incubation of the plasma samples with 50/2g/ml horseradish 
peroxidase (HRP) and 250/2M hydrogen peroxide for 2 h at 37°C, 
followed by incubation with 250 ,uM peroxynitrite for 1 h at 37°C 
caused maximal oxidation of DHR 123. Plasma levels of DHR 123 in 
the rats amounted to 1.07 + 0.12/2M (n -- 6), thus providing a concen- 
tration comparable for the ones used to measure peroxynitrite in in 
vitro studies (see also [14]). The amounts of rhodamine formed in vivo 
were quantified by using a rhodamine standard curve (1-30 nM) pre- 
pared in plasma obtained from untreated rats. Background plasma 
fluorescence was subtracted from all samples. 
2.4. EfJect of*NO on peroxynitrite-mediated oxidation of DHR 123 
in vitro 
In a separate set of studies, the effect of °NO on the peroxynitrite- 
mediated oxidation of DHR 123 was studied in vitro. These studies 
were performed in phosphate-buffered saline (PBS) containing 100/2M 
diethylenepentaacetic acid (DTPA), pH 7.4. Nitric oxide was generated 
by the dissolution of the *NO donor NONO-ate compound iethylam- 
ine:NO. The oxidation of DHR 123 by peroxynitrite (1 /.tM) 
or hydrogen peroxide (1/2M) plus 25/2g/ml HRP in the presence of 
various concentrations of the *NO donor to generate °NO at rates of 
0. l, 1/2M/rain and 10/2M/rain, was measured by the change in absorb- 
ance at 500 nm (e = 78,000 M -a. cm -~) after 30 rain incubation at 37 ° C 
[19]. 
2.5. Statistical evaluation 
Values are expressed as mean+standard e ror of the mean ofn obser- 
vations. In vivo, n = 4-6 animals were used in each time point; in the 
in vitro studies, n = 3-6 samples were used. Student's unpaired t-test 
was used to compare means between groups. A P-value less than 0.05 
was considered to be statistically significant. 
3. Results 
In normal, control rats, inhibit ion of ecNOS by L-NAME 
caused a significant, approximately two-fold increase in the 
rhodamine fluorescence in the plasma (Fig. 1). Injection of 
endotoxin caused a significant (approximately six times) in- 
crease in rhodamine fluorescence within lh  (Fig. la). The in- 
creased rhodamine fluorescence persisted at 2 h and 3 h after 
endotoxic shock (Fig. la). The increase in DHR 123 oxidation 
during 1-3 h following endotoxin treatment was prevented by 
inhibit ion of NOS (with L-NAME at 1 h or with SMT at 2 or 
3 h) (Fig. la). 
In hemorrhagic shock, similarly to endotoxic shock, we ob- 
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Fig. 1. Plasma levels of rhodamine in control rats (C), in rats at 1, 2 
and 3 h after bacterial lipopolysaccharide (LPS) (a), at 1 and 3 h after 
hemorrhagic shock (HS) (b), and in the ischemic (SAO) and reperfusion 
(SAO/R) phase of splanchnic artery occlusion/reperfusion shock (c). 
Closed bars represent the rhodamine levels without NOS inhibitors, 
open bars depict rhodamine levels in the presence of NOS inhibitors 
(see Methods). *'**Represent significant increase in rhodamine fluores- 
cence in shock (P < 0.05, P < 0.01, resp.); URepresents significant effect 
of the NOS inhibitor at the same time point (P < 0.05). 
served a 9-fold increase in the rhodamine fluorescence in the 
plasma as early as 1 h after the initiation of bleeding (Fig. lb), 
and the increased fluorescence persisted at 3 h after hemor- 
rhagic shock. Inhibit ion of NOS reduced rhodamine fluores- 
cence both in the early and delayed phase of hemorrhagic shock 
(Fig. Ib). 
In splanchnic ischemia/reperfusion, no marked increase in 
the rhodamine fluorescence was observed at the early (is- 
chemic) phase of shock, but there was a four-fold increase in 
the reperfusion phase, which was inhibited by L-NAME (Fig. 
lc). 
The finding that L-NAME caused an increase in the fluores- 
cence of rhodamine in the plasma samples of control animals, 
led us to investigate the effect of *NO on the peroxynitrite- 
mediated oxidation of DHR 123 in vitro. We observed that a 
ten-fold excess of *NO (generated by the .NO donor  corn- 
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Fig. 2. Effect of*NO in the oxidation of 10 mM DHR 123 by chemically 
synthesized peroxynitrite (a) or hydrogen peroxide plus HRP (b) in PBS 
containg 100 ¢tM DTPA, pH 7.4 for 30 rain at 37°C. -NO was gener- 
ated by diethylamine:NO and diethylamine was used as control. The 
oxidation of DHR 123 to rhodamine was measured by the change in 
absorbance at500 nm. **Represents significant inhibition of the oxida- 
tion of DHR 123 by *NO (P < 0.01). 
pound diethylamine: NO) causes a marked suppression of the 
oxidation of DHR 123 by peroxynitrite (Fig. 2a). Lower con- 
centrations of *NO, however, did not cause such inhibition 
(Fig. 2a). Similarly, a ten-fold excess of °NO inhibited 
the hydrogen peroxide/HRP-induced oxidation of DHR 123 
(Fig. 2b). 
4. Discussion 
A substantial increase in nitrotyrosine immunoreactivity, a 
specific marker of peroxynitrite has been demonstrated in the 
delayed phase of end,toxic shock [3,4]. The oxidation of DHR 
123 by peroxynitrite has been successfully utilized for the meas- 
urement of peroxynitrite formation in vitro [4,14]. The method 
is sensitive and specific, since neither *NO nor superoxide 
causes DHR 123 oxidation [14]. However, it is noteworthy that, 
in addition to peroxynitrite, hydrogen peroxide in the presence 
of horseradish peroxidase, and superoxide plus hydrogen per- 
oxide in the presence of a metal catalyst are known to oxidize 
DHR 123 to rhodamine [20]. 
Here we monitored the NOS-inhibitor inhibitable oxidation 
of DHR 123 in the plasma of rats subjected to shock and we 
found an increase in the oxidation of DHR 123 to rhodamine 
already in the early phase. The enhanced formation of per- 
oxynitrite, in these early stages of shock is: (1) due to an *NO- 
related species, since it is inhibited by NOS inhibitors; (2) but 
not due to oN*, as oN* alone does not increase oxidation of 
DHR 123 [14]; and (3) therefore it is presumably due to per- 
oxynitrite. Within 1 h of end,toxic or hemorrhagic shock, per- 
oxynitrite must be formed by a reaction of superoxide (pro- 
duced by activated neutrophils, macrophages, endothelial cells) 
with *NO derived from the constitutive, ndothelial is,form of 
NOS (ecNOS), since expression of iNOS does not occur until 
later stages of shock [15-17,21,22]. Thus, peroxynitrite is 
formed at a very early stage of various forms of shock; its 
precursor, oN*, is derived, at this stage, from ecNOS rather 
than iN*S, and thus the rate limiting factor in the production 
of peroxynitrite in shock may be superoxide, rather than oN*. 
At later stages of end,toxic and hemorrhagic shock, such as 
at 3 h, we have previously confirmed the induction of iNOS in 
the shock models used in the present study [15-17,21,22]. In- 
creased oxidation of DHR 123 to rhodamine persisted at these 
later stages of shock and could be inhibited by inhibition of 
NOS. Unexpectedly, however, we did not observe a massive 
increase in rhodamine at these later stages. 
This latter finding, and the observation that the oxidation of 
DHR 123 is enhanced by L-NAME in control animals, may be 
explained, in part, by our in vitro results, demonstrating that 
the peroxynitrite-mediated an the hydrogen peroxide/HRP- 
mediated oxidation of DHR 123 is inhibited by °NO. A likely 
explanation is the following: oxidation of DHR 123 by either 
peroxynitrite or H2O 2 in the presence of HRP proceeds via a 
one-electron oxidation to form a radical-DHR 123 intermedi- 
ate. A second one-electron oxidation will form the final oxida- 
tion product rhodamine. The presence of °NO in excess over 
either peroxynitrite or H202 would reduce the oxidation of 
DHR 123 because .NO would react with the one electron 
intermediate o give back the original compound plus nitrite. 
Similar, *NO-mediated inhibition of peroxynitrite-mediated 
lipid peroxidation has been recently described [23]. It is note- 
worthy that the peroxynitrite-mediated d velopment of endo- 
thelial dysfunction can be inhibited by .NO donor compounds 
[24], and peroxynitrite-mediated cytotoxicity in macrophages is 
inhibited by °NO donors in vitro (authors' unpublished). 
Although NO-mediated inhibition of DHR 123 oxidation is 
an attractive hypothesis to explain the increase in DHR 123 
oxidation by L-NAME in control rats and the lack of massive 
increase in rhodamine oxidation in later stages of shock, other 
possibilities also have to be considered. In perfused mesentery, 
similar to our observation, oxidation of DHR 123 increases 
after inhibition ofecNOS by L-NAME [25], an effect, which has 
been attributed to increased leukocyte activation and hydrogen 
peroxide production [25] In addition, in the delayed state of 
shock, peroxynitrite and other oxidants may increase cell per- 
meability which may result in an increase of rhodamine trapped 
in the tissue, thereby reducing the levels of rhodamine detected 
in the plasma. 
Our data suggest hat peroxynitrite is present and may be 
injurious already at earlier stages of shock, when *NO is not 
yet produced in excessive amounts. Peroxynitrite-mediated in- 
jury may explain the protective ffect of L-NAME and ecNOS 
inhibition in conditions associated with superoxide overpro- 
duction, such as paraqat mediated lung injury [26], or myocar- 
dial ischemia-reoxygenation injury [27], and cerebral ischemia- 
reperfusion [28] where inhibition of ecNOS has beneficial ef- 
fects. At later stages of shock, excess °NO may reduce the 
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peroxynitrite-mediated injury, but, large amounts of *NO may 
directly cause injury. The complex interactions between *NO 
and peroxynitrite in vitro and in vivo, require further investiga- 
tions. 
The early formation of peroxynitrite necessitates the intro- 
duction of different therapeutic strategies, especially in the 
early stage of shock. Peroxynitrite has cytotoxic actions that 
may be, in part, different from that of *NO involving effects 
leading to endothelial dysfunction [24], inhibiting key enzymes 
of the mitochondrial respiratory chain [29], causing DNA 
strand breaks [30] and depleting intracellular high energy phos- 
phate levels due to activation of energy-consuming DNA repair 
processes [30]. 
Thus, the oxidation of dihydrorhodamine is increased in 
shock and ischemia/reperfusion. Measurement of NOS-inhibi- 
tor-inhibitable oxidation of dihydrorhodamine may be useful 
in investigating peroxynitrite formation in pathophysiological 
conditions associated with *NO and superoxide production. 
The method, however, results in under-estimation f the abso- 
lute amounts of peroxynitrite because of inhibition of the oxi- 
dation of DHR 123 by excess eNO; enhancement of hydrogen 
peroxide production and oxidation of DHR 123 by NOS inhib- 
itors due to white cell activation, and scavenging of a portion 
of peroxynitrite prior to its reaction with DHR 123 by plasma 
components such as uric acid and proteins [14, 31], which are 
present at concentrations higher than DHR 123. 
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